Hypertension outcomes of adrenalectomy for unilateral primary
aldosteronism

J 2022

Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism

HARTMANN, Igor, Frantisek HRUSKA, Jan VACLAVIK, Eva KOCIANOVA, Zdenek FRYSAK et. al.

Základní údaje

Originální název

Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism

Autoři

HARTMANN, Igor, Frantisek HRUSKA (203 Česká republika, garant), Jan VACLAVIK (203 Česká republika), Eva KOCIANOVA (203 Česká republika), Zdenek FRYSAK (203 Česká republika), Marika NESVADBOVA (203 Česká republika), Zbynek TUDOS (203 Česká republika), Filip CTVRTLIK (203 Česká republika) a Klára BENEŠOVÁ (203 Česká republika, domácí)

Vydání

ENDOCRINE, NEW YORK, SPRINGER, 2022, 1355-008X

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30202 Endocrinology and metabolism

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.700

Kód RIV

RIV/00216224:14110/22:00128270

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1007/s12020-022-02988-y

UT WoS

000754153800002

Klíčová slova anglicky

Primary aldosteronism; Secondary hypertension; Daily defined dose; Antihypertensive drug treatment; Unilateral adrenalectomy

Štítky

14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 12:43, Mgr. Tereza Miškechová

Anotace

V originále

Purpose To evaluate laboratory and clinical results after unilateral adrenalectomy in patients with primary aldosteronism (PHA). Methods A cross-sectional analysis was performed using data from patients who underwent transperitoneal laparoscopic adrenalectomy for PHA, between January 2008 and December 2019. Surgical indications were based on adrenal venous sampling without ACTH stimulation. Analyses included patient demographics; preoperative clinical, pharmacological, laboratory, and radiological data; and postoperative results assessed after a median of 4 months. Antihypertensive drug use was quantified by estimating the daily defined dose (DDD) of antihypertensive medication, thus enabling standardized comparison of dosage between the drug classes. Statistical assessments included univariable and multivariable logistic regression analysis. Results This study enrolled 87 patients. The patients were taking 5.4 DDD of antihypertensive medication before surgery, and 3.0 DDD after surgery. Complete biochemical success of surgery was reached 67 patients (77%), 19 patients (22%) had partial biochemical success. Complete clinical success with normalization of blood pressure and withdrawal of all antihypertensive drugs was achieved in 19 patients (22%). 57 patients (65%) exhibited a reduction of DDD after surgery and/or improvement of blood pressure-partial clinical success. Thus, in 76 (87%) of all enrolled patients, surgery had an overall positive effect on hypertension control. Multivariable logistic regression showed that complete clinical success was independently associated with female gender and baseline sum of antihypertensive drugs DDD < 4. Conclusion A majority of patients undergoing unilateral adrenalectomy for PHA achieved markedly improved hypertension control, despite almost halving their antihypertensive medication. Almost a quarter of patients were cured and able to cease using all antihypertensive drugs.

Citovat

HARTMANN, Igor, Frantisek HRUSKA, Jan VACLAVIK, Eva KOCIANOVA, Zdenek FRYSAK, Marika NESVADBOVA, Zbynek TUDOS, Filip CTVRTLIK a Klára BENEŠOVÁ. Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism. ENDOCRINE. NEW YORK: SPRINGER, 2022, roč. 76, č. 1, s. 142-150. ISSN 1355-008X. Dostupné z: https://dx.doi.org/10.1007/s12020-022-02988-y.

@article{2249608,
   author = {Hartmann, Igor and Hruska, Frantisek and Vaclavik, Jan and Kocianova, Eva and Frysak, Zdenek and Nesvadbova, Marika and Tudos, Zbynek and Ctvrtlik, Filip and Benešová, Klára},
   article_location = {NEW YORK},
   article_number = {1},
   doi = {http://dx.doi.org/10.1007/s12020-022-02988-y},
   keywords = {Primary aldosteronism; Secondary hypertension; Daily defined dose; Antihypertensive drug treatment; Unilateral adrenalectomy},
   language = {eng},
   issn = {1355-008X},
   journal = {ENDOCRINE},
   title = {Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism},
   url = {https://link.springer.com/article/10.1007/s12020-022-02988-y},
   volume = {76},
   year = {2022}
}

TY  - JOUR
ID  - 2249608
AU  - Hartmann, Igor - Hruska, Frantisek - Vaclavik, Jan - Kocianova, Eva - Frysak, Zdenek - Nesvadbova, Marika - Tudos, Zbynek - Ctvrtlik, Filip - Benešová, Klára
PY  - 2022
TI  - Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism
JF  - ENDOCRINE
VL  - 76
IS  - 1
SP  - 142-150
EP  - 142-150
PB  - SPRINGER
SN  - 1355008X
KW  - Primary aldosteronism
KW  - Secondary hypertension
KW  - Daily defined dose
KW  - Antihypertensive drug treatment
KW  - Unilateral adrenalectomy
UR  - https://link.springer.com/article/10.1007/s12020-022-02988-y
N2  - Purpose To evaluate laboratory and clinical results after unilateral adrenalectomy in patients with primary aldosteronism (PHA). Methods A cross-sectional analysis was performed using data from patients who underwent transperitoneal laparoscopic adrenalectomy for PHA, between January 2008 and December 2019. Surgical indications were based on adrenal venous sampling without ACTH stimulation. Analyses included patient demographics; preoperative clinical, pharmacological, laboratory, and radiological data; and postoperative results assessed after a median of 4 months. Antihypertensive drug use was quantified by estimating the daily defined dose (DDD) of antihypertensive medication, thus enabling standardized comparison of dosage between the drug classes. Statistical assessments included univariable and multivariable logistic regression analysis. Results This study enrolled 87 patients. The patients were taking 5.4 DDD of antihypertensive medication before surgery, and 3.0 DDD after surgery. Complete biochemical success of surgery was reached 67 patients (77%), 19 patients (22%) had partial biochemical success. Complete clinical success with normalization of blood pressure and withdrawal of all antihypertensive drugs was achieved in 19 patients (22%). 57 patients (65%) exhibited a reduction of DDD after surgery and/or improvement of blood pressure-partial clinical success. Thus, in 76 (87%) of all enrolled patients, surgery had an overall positive effect on hypertension control. Multivariable logistic regression showed that complete clinical success was independently associated with female gender and baseline sum of antihypertensive drugs DDD < 4. Conclusion A majority of patients undergoing unilateral adrenalectomy for PHA achieved markedly improved hypertension control, despite almost halving their antihypertensive medication. Almost a quarter of patients were cured and able to cease using all antihypertensive drugs.
ER  -

HARTMANN, Igor, Frantisek HRUSKA, Jan VACLAVIK, Eva KOCIANOVA, Zdenek FRYSAK, Marika NESVADBOVA, Zbynek TUDOS, Filip CTVRTLIK a Klára BENEŠOVÁ. Hypertension outcomes of adrenalectomy for unilateral primary aldosteronism. \textit{ENDOCRINE}. NEW YORK: SPRINGER, 2022, roč.~76, č.~1, s.~142-150. ISSN~1355-008X. Dostupné z: https://dx.doi.org/10.1007/s12020-022-02988-y.

Podrobný výpis o publikaci